Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement Briefs: National Coverage Updates; MolDx Meeting Request; Sleep Study Questions

This article was originally published in The Gray Sheet

Executive Summary

Hepatitis C virus screening national coverage supported in comments. Proposed decision memo delayed for percutaneous image-guided lumbar decompression for lumbar spinal stenosis national coverage determination. More reimbursement news.

You may also be interested in...



News Briefs: Biomet IPO; Hep C Screening Coverage; Valve Guidelines

Biomet’s parent company filed an initial public offering registration statement for the firm March 7. CMS proposes national coverage for hepatitis C screening. ACC and AHA release new heart valve guidelines. More news.

CMS Proposes Noncoverage For Percutaneous Image-guided Lumbar Decompression

The procedure, aimed at treating lumbar spinal stenosis, is not reasonable and necessary, the Medicare agency says. A final decision is due Jan. 15.

MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes

Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as concerns about perceived changes to the gap-fill regulation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel